

Gastric Surgery Division

Introduction

In the Hospital East, there is no independent Gastric Surgery Group. Surgeons in the Hepatobiliary and Pancreatic Surgery Group and Colorectal Surgery Group operate on patients with gastric and duodenal malignancies including adenocarcinomas, myogenic tumors and others neoplasms.

Daily Activities

In close cooperation with surgeons in the two abdominal surgery groups, five to six patients are operated on every week.

Every Monday from 4:30 to 5:30 p.m., a film conference of the gastrointestinal malignancy is held, where treatment decisions are discussed especially for surgical cases among medical oncologists, endoscopists, radiologists and surgeons. Operative findings and pathological findings of resected specimens are reported in this conference. This conference is held in English when any foreign guest doctor is present.

Research Activities

1. Assessment of combined modalities

1) JCOG trial 0001: A phase II trial to confirm the feasibility and effectiveness of neo-adjuvant chemotherapy using CPT-11 + CDDP for the patient with bulky N2 or N3. This trial was finished in this year.

2) JCOG trial 0002-DI : A phase II trial to confirm the feasibility and effectiveness of neoadjuvant chemotherapy using TS-1 for the patient with typical

scirrhous gastric cancer. This trial was closed with scheduled recruitment of 55 patients. This trial was finished in this year.

3) ACTS-GC trial: a phase III trial of adjuvant chemotherapy using TS-1 for curatively resected gastric cancer patients (stage II-III, except for early gastric cancer patient). This trial is still ongoing.

4) JCOG trial 0210: A phase II trial to evaluate feasibility and efficacy of neoadjuvant chemotherapy using TS-1 + CDDP for large sized type 3 and type 4 gastric cancer. This trial was closed in this year.

2. Assessment of surgical procedures

1) JCOG trial 9501: A randomized trial comparing two commonly used approaches for gastric cancer invading the esophagus. In this trial, the 5-year survival rate is the primary endpoint and postoperative morbidity, mortality and QOL will be evaluated. This trial was closed by the results of interim analysis, which showed very low possibility to demonstrate superiority of thoraco-abdominal approach.

2) JCOG trial 0110: A phase III trial to confirm the efficacy of splenectomy for the patients with cancer in the upper part of the stomach.

3) A pilot study to evaluate efficacy of FDG injection to detect metastatic lymph node during an operation.

New Developments

In 2004, a new JCOG trial to evaluate feasibility and accuracy of sentinel node biopsy in early gastric cancer will start.

● T.Kinoshita ●

Number of Patients

Primary gastric cancer	282
Recurrent gastric cancer	6

Total	288
-------	-----

Operative procedures

Total gastrectomy	71
Proximal gastrectomy	29
Distal gastrectomy	156
Partial resection	3
Staging laparoscopy	5
Bypass	8
Exploratory laparotomy	10
Others	6

Total	288
-------	-----